Recursion Pharmaceuticals, Inc. (RXRX): Free Cash Flow
-$378.28M
Year ended 2025-12-31
-$352.27M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$378.28M | n/m | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | -$372.87M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$299.74M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$120.58M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$198.41M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$51.23M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$60.95M | n/a | 2022-03-23, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | -$378.28M | n/m |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | -$302.61M | n/m |
| Compugen Ltd (CGEN) | 2025-12-31 | $31.33M | -36.7% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | -$62.30M | n/m |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | -$396.61M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$50.19M | n/m |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | -$109.62M | n/m |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$5.04M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$58.29M | n/m |
Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗